Last reviewed · How we verify
Anti-congestive treatment
Anti-congestive treatment is a Small molecule drug developed by Hillel Yaffe Medical Center. It is currently in Phase 3 development for Congestion associated with heart failure or related conditions. Also known as: Diuretic therapy.
Anti-congestive treatment reduces fluid accumulation and improves hemodynamic function in patients with congestion-related conditions.
Anti-congestive treatment reduces fluid accumulation and improves hemodynamic function in patients with congestion-related conditions. Used for Congestion associated with heart failure or related conditions.
At a glance
| Generic name | Anti-congestive treatment |
|---|---|
| Also known as | Diuretic therapy |
| Sponsor | Hillel Yaffe Medical Center |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The drug works to alleviate congestion by reducing excessive fluid retention and improving cardiac or vascular function. The specific molecular mechanism is not publicly detailed, but anti-congestive agents typically work through diuretic, vasodilatory, or inotropic pathways to restore normal fluid balance and tissue perfusion.
Approved indications
- Congestion associated with heart failure or related conditions
Common side effects
Key clinical trials
- IC14 for Treatment of Acute Decompensated Heart Failure (PHASE1, PHASE2)
- Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation (PHASE2)
- Chest U/S in Differentiating Lung Congestion & Pneumonia in Adult Critically-ill Patients and Its Prognostic Impact
- Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD (PHASE4)
- Simvastatin Therapy in Patients With Dilated Cardiomyopathy. (PHASE2)
- How to Prevent Heart Failure Readmission by Using Lung Impedance Device (HOPE-HF Study) (PHASE3)
- Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-congestive treatment CI brief — competitive landscape report
- Anti-congestive treatment updates RSS · CI watch RSS
- Hillel Yaffe Medical Center portfolio CI
Frequently asked questions about Anti-congestive treatment
What is Anti-congestive treatment?
How does Anti-congestive treatment work?
What is Anti-congestive treatment used for?
Who makes Anti-congestive treatment?
Is Anti-congestive treatment also known as anything else?
What development phase is Anti-congestive treatment in?
Related
- Manufacturer: Hillel Yaffe Medical Center — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Congestion associated with heart failure or related conditions
- Also known as: Diuretic therapy
- Compare: Anti-congestive treatment vs similar drugs
- Pricing: Anti-congestive treatment cost, discount & access